PSEN1 and Mental deterioration: APP/PS1 female mice were treated with CP2 or vehicle starting at 9 months of age, after the onset of cognitive decline and neurodegeneration, to test the efficacy of this novel therapeutic strategy under conditions most relevant to patients (Figure 1a) [34].